Peptide Therapy, Online
GLP-1s, Sermorelin, NAD+, PT-141, glutathione, low dose naltrexone, and select prescription skincare options — reviewed by licensed providers and delivered through appropriate pharmacy partners.
Affinity Direct's peptide and wellness program will focus on treatments available through Affinity Whole Health's current clinical offerings: GLP-1s, Sermorelin, NAD+, PT-141, GHK-Cu copper peptide cream, tretinoin + niacinamide serum, low dose naltrexone, and glutathione.
GLP-1s for Weight Management
Glucagon-like peptide-1 (GLP-1) is a hormone released by the intestines after eating. It regulates blood sugar by stimulating insulin release, and signals the brain to reduce appetite. Synthetic GLP-1 receptor agonists work by mimicking this hormone at sustained levels — producing effects far beyond what the body's natural GLP-1 pulse achieves.
Semaglutide is the most studied GLP-1 receptor agonist. The landmark STEP-1 trial (New England Journal of Medicine, 2021) enrolled 1,961 patients and showed:
- 14.9% average body weight reduction at 68 weeks (vs. 2.4% for placebo)
- 86% of semaglutide patients lost ≥5% of body weight (vs. 32% placebo)
- 69% lost ≥10% of body weight (vs. 12% placebo)
These results represent the most effective non-surgical weight loss medication ever studied in clinical trials. Semaglutide is FDA-approved as Wegovy (2.4mg weekly) for chronic weight management and as Ozempic for type 2 diabetes. Provider supervision is required for both.
Who is a candidate: Adults with BMI ≥30, or BMI ≥27 with a weight-related condition (type 2 diabetes, hypertension, sleep apnea, or elevated cardiovascular risk). A provider evaluation is required to determine appropriateness.
Semaglutide is administered as a weekly subcutaneous injection. It is titrated up gradually over several months — a slow dose escalation protocol that minimizes gastrointestinal side effects. The STEP-4 trial demonstrated that weight regain occurs after discontinuation, indicating this is a long-term treatment for a chronic condition.
Additional Wellness Options
Beyond GLP-1s, Affinity Whole Health offers select wellness protocols that may be available online as the program expands:
- Sermorelin — a growth-hormone-releasing hormone analog considered by a provider when clinically appropriate.
- NAD+ — a cellular health and wellness protocol offered through Affinity Whole Health.
- PT-141 — a sexual wellness treatment evaluated case by case.
- Glutathione and low dose naltrexone — wellness protocols that require provider review and appropriate prescribing.
- GHK-Cu copper peptide cream and tretinoin + niacinamide serum — prescription skincare options that may be offered through the skin health program.
Availability depends on state, pharmacy access, clinical appropriateness, and current prescribing rules. We do not list treatments online that Affinity does not offer.
What to Expect from Affinity Direct
Our approach to peptide therapy will reflect the same clinical rigor that defines our ED treatment program:
- Comprehensive intake — health history, weight history, current medications, and goals
- Lab work if needed — GLP-1 eligibility may require metabolic labs; providers will order what is clinically appropriate
- Provider review and prescription — licensed provider determines the appropriate protocol and prescribes through appropriate channels only
- Ongoing monitoring — regular check-ins to track response, adjust dosing, and manage side effects
Common Questions
What are peptides?
Peptides are short chains of amino acids that act as biological signaling molecules. In therapeutic contexts, they bind to specific receptors to trigger targeted physiological responses. GLP-1 receptor agonists are the most clinically validated peptide class — they mimic a gut hormone that regulates appetite and blood sugar, producing significant and sustained weight loss.
What peptides are used for weight loss?
GLP-1 receptor agonists are the primary evidence-based class for weight loss. Semaglutide (Wegovy, Ozempic) showed 14.9% average weight reduction in the STEP-1 trial. Tirzepatide (a dual GIP/GLP-1 agonist, brand names Zepbound and Mounjaro) has shown even higher efficacy in subsequent trials. Both are FDA-approved and require a prescription.
Are peptides FDA-approved?
It depends on the specific treatment. GLP-1 medications include FDA-approved options for weight management or diabetes. Other wellness protocols vary by ingredient, indication, and compounding rules. Affinity providers only prescribe treatments that are clinically appropriate and available through our pharmacy partners.
What is semaglutide?
Semaglutide is a synthetic GLP-1 receptor agonist administered as a weekly subcutaneous injection. It works by mimicking the gut hormone GLP-1, slowing gastric emptying and reducing appetite signals in the brain. FDA-approved as Wegovy for weight management and Ozempic for type 2 diabetes. It is the most studied and effective non-surgical weight loss medication available.
Is peptide therapy safe?
Safety depends entirely on the specific peptide. FDA-approved GLP-1 medications have well-characterized safety data from large clinical trials. The most common side effects are gastrointestinal (nausea, typically mild and resolving with dose titration). Non-approved research peptides carry greater uncertainty and should never be used outside of strict clinical oversight with full understanding of their investigational status.
Peptide therapy is coming to Affinity Direct
Join the waitlist to be notified when GLP-1, peptide, and wellness programs are available through our platform.
Join the Waitlist →Peptide and wellness protocols vary in FDA-approval status and availability. Affinity providers only prescribe treatments that are clinically appropriate and available through approved pharmacy channels. This page is informational only and does not constitute medical advice. All prescriptions require a provider evaluation. Last reviewed: May 2026.